VaxSyn

DB17827InvestigationalVaccines

VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

Mechanism: Pharmacologically active on Envelope glycoprotein gp160
Curator reviewed
Also known as: Gp160 Vaccine · HIV gp160 vaccine · Human T-lymphotropic virus type III Gp160 antigens · Recombinant gp160 vaccine · VaxSyn HIV-1

Resolves to

Targets

P12488env

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with VaxSyn, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account